Loading...

Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data

Canagliflozin (CFZ) is a member of new class of glucose lowering agents, sodium-glucose co-transporter (SGLT) inhibitors, which got approval by food and drug administration. It has insulin independent action by blocking the transporter protein SGLT2 in the kidneys, resulting in urinary glucose excre...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Bhatia, Jagriti, Gamad, Nanda, Bharti, Saurabh, Arya, Dharamvir Singh
Format: Artigo
Sprog:Inglês
Udgivet: Baishideng Publishing Group Inc 2014
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4058745/
https://ncbi.nlm.nih.gov/pubmed/24936262
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4239/wjd.v5.i3.399
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!